Search results for "Surrogate endpoint"

showing 10 items of 71 documents

Duration of previous treatment as a prognostic factor in metastatic colorectal cancer treated with trifluridine/tipiracil

2018

We herein describe the findings from the trifluridine/tipiracil (TAS-102) Compassionate Use program in Latvia, set up prior to marketing authorization for the management of pretreated patients with metastatic colorectal cancer (mCRC). The efficacy and safety of TAS-102 in patients with refractory mCRC were evaluated in the phase III trial RECOURSE. A previous report confirmed neutropenia and duration of previous treatment for mCRC as prognostic factors in TAS-102 users. The aim of the present study was to analyze possible prognostic factors, such as neutropenia, in TAS-102 responders. A retrospective analysis of 14 patients who received TAS-102 chemotherapy in two institutions in Latvia (Cl…

0301 basic medicineCancer ResearchChemotherapymedicine.medical_specialtySurrogate endpointColorectal cancerbusiness.industrymedicine.medical_treatmentHazard ratioCancerArticlesNeutropeniamedicine.disease03 medical and health scienceschemistry.chemical_compound030104 developmental biology0302 clinical medicineOncologyRefractorychemistry030220 oncology & carcinogenesisInternal medicinemedicinebusinessTipiracilMolecular and Clinical Oncology
researchProduct

Effects of Immunonutrition in Advanced Human Immunodeficiency Virus Disease: A Randomized Placebo-controlled Clinical Trial (Promaltia Study)

2018

[Background]: While nutritional interventions with prebiotics and probiotics seem to exert immunological effects, their clinical implications in human immunodeficiency virus (HIV)–infected subjects initiating antiretroviral therapy (ART) at advanced HIV disease remain unclear.

0301 basic medicineMicrobiology (medical)medicine.medical_specialtySynbioticsCD4 T cellsPlaceboGastroenterologylaw.invention03 medical and health sciences0302 clinical medicineRandomized controlled trialAcquired immunodeficiency syndrome (AIDS)lawInternal medicinemedicineImmunoactivation030212 general & internal medicineYoung adultAdverse effectInflammationbusiness.industrySurrogate endpointMicrobiotaProbioticsvirus diseasesmedicine.diseaseClinical trial030104 developmental biologyInfectious DiseasesbusinessClinical Infectious Diseases
researchProduct

Baseline Splenic Volume as a Prognostic Biomarker of FOLFIRI Efficacy and a Surrogate Marker of MDSC Accumulation in Metastatic Colorectal Carcinoma

2020

Background: Predictive biomarkers of response to chemotherapy plus antiangiogenic for metastatic colorectal cancer (mCRC) are lacking. The objective of this study was to test the prognostic role of splenomegaly on baseline CT scan. Methods: This study is a sub-study of PRODIGE-9 study, which included 488 mCRC patients treated by 5-fluorouracil, leucovorin and irinotecan (FOLFIRI) and bevacizumab in first line. The association between splenic volume, and PFS and OS was evaluated by univariate and multivariable Cox analyses. The relation between circulating monocytic Myeloid derived suppressor cells (mMDSC) and splenomegaly was also determined. Results: Baseline splenic volume &gt

0301 basic medicineOncologyCancer Researchmedicine.medical_specialtyBevacizumabColorectal cancermedicine.medical_treatment[SDV]Life Sciences [q-bio]MDSClcsh:RC254-282Article03 medical and health sciences0302 clinical medicineInternal medicineMedicinePrognostic biomarkerprognostic biomarkerChemotherapysplenomegalybusiness.industrySurrogate endpointmetastatic colorectal cancerlcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.diseasedigestive system diseases3. Good healthIrinotecan030104 developmental biologyOncology030220 oncology & carcinogenesisMyeloid-derived Suppressor CellFOLFIRIcirculating monocytic myeloid derived suppressor cellsbusinessmedicine.drugCancers
researchProduct

The Role of Molecular Profiling to Predict the Response to Immune Checkpoint Inhibitors in Lung Cancer.

2019

Immune checkpoint inhibitors radically changed the treatment of patients with non-small cell lung cancer (NSCLC). However, only one-quarter of patients benefit from these new therapies when used as monotherapy. The assessment of Program Death Ligand-1 (PD-L1) tumor expression by immunohistochemistry is used to select potential responder patients, but this not an optimal marker since it does not predict the absence of anti PD-1 efficacy. Despite this shortcoming, PD-L1 remains the gold standard biomarker in many studies and the only biomarker available for clinicians. In addition to histological markers, transcriptomic and exome analyses have revealed potential biomarkers requiring further c…

0301 basic medicineOncologyCancer Researchmedicine.medical_specialtymedicine.medical_treatmentImmune checkpoint inhibitorsReviewlcsh:RC254-282Transcriptome03 medical and health sciences0302 clinical medicineInternal medicinemedicineLung cancerExomebusiness.industrySurrogate endpointbiomarkersImmunotherapymedicine.diseaselcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens030104 developmental biologyOncology030220 oncology & carcinogenesisBiomarker (medicine)ImmunohistochemistryimmunotherapyLung cancerbusinessCancers
researchProduct

Progression-free survival as a surrogate endpoint of overall survival in patients with metastatic colorectal cancer

2018

Giuseppe Cicero,1 Rossella De Luca,1 Francesco Dieli2 1Department of Surgical, Oncological and Oral Sciences, Section of Medical Oncology, University of Palermo, Palermo, Italy; 2Central Laboratory of Advanced Diagnosis and Biomedical Research (CLADIBIOR), University of Palermo, Palermo, Italy Background: In many clinical trials designed to assess the efficacy of anticancer treatments, overall survival (OS) is often used as a primary endpoint despite its several points of weakness. Methods: This study evaluated the role of progression-free survival (PFS) in the first three lines of treatment as a potential surrogate endpoint of OS in patients with metastatic colorectal cancer (MCRC). One hu…

0301 basic medicineOncologymedicine.medical_specialtycolorectal neoplasm overall survival progression-free survival surrogate endpoint liver metastates avastin egorafenibColorectal canceroverall survivalegorafenibOncoTargets and Therapy03 medical and health sciences0302 clinical medicineInternal medicinesurrogate endpoint liver metastatesOverall survivalClinical endpointMedicinePharmacology (medical)In patientProgression-free survivalavastinOriginal Researchbusiness.industryTime to progressionSurrogate endpointmedicine.diseaseClinical trial030104 developmental biologyOncology030220 oncology & carcinogenesiscolorectal neoplasmbusinessprogression-free survivalOncoTargets and Therapy
researchProduct

Is it time to combine untargeted antifungal strategies to reach the goal of 'early' effective treatment?

2016

A recently published retrospective study by Posteraro et al. [1] investigated the use of (1–3)-β-D-glucan (BDG) as a strategy for antifungal drug administration in patients at high risk of candidemia. The strategy consisted of the administration of antifungals (anidulafungin in most cases) to septic patients with a Candida score ≥ 3a nd a positive BDG result (≥80 pg/ml). This untargeted strategy led to better selection of patients, avoiding exposure to antifungals in approximately 73 % of patients with negative BDG results and leading to shortened treatment duration in another 20 % of patients. Untargeted antifungal treatments (including prophylaxis, pre-emptive and empiric approaches) are …

0301 basic medicinemedicine.medical_specialtyAntifungal Agents030106 microbiologyAntifungal drugCritical Care and Intensive Care Medicinelaw.inventionGoal03 medical and health sciences0302 clinical medicineRandomized controlled triallawmedicineHumans; Treatment Outcome; Antifungal Agents; Goals; Critical Care and Intensive Care MedicineAntifungal AgentHumansStage (cooking)MED/41 - ANESTESIOLOGIAAdverse effectIntensive care medicineSurrogate endpointbusiness.industryIncidence (epidemiology)030208 emergency & critical care medicineRetrospective cohort studyTreatment OutcomeAnidulafunginbusinessGoalsmedicine.drugHumanCritical care (London, England)
researchProduct

Definition and significance of polycystic ovarian morphology: a task force report from the Androgen Excess and Polycystic Ovary Syndrome Society

2014

BACKGROUND The diagnosis of polycystic ovary syndrome (PCOS) relies on clinical, biological and morphological criteria. With the advent of ultrasonography, follicle excess has become the main aspect of polycystic ovarian morphology (PCOM). Since 2003, most investigators have used a threshold of 12 follicles (measuring 2-9 mm in diameter) per whole ovary, but that now seems obsolete. An increase in ovarian volume (OV) and/or area may also be considered accurate markers of PCOM, yet their utility compared with follicle excess remains unclear. METHODS Published peer-reviewed medical literature about PCOM was searched using PubMed.gov online facilities and was submitted to critical assessment b…

AdultAnti-Mullerian Hormonemedicine.medical_specialtyAdolescentPopulationOvaryBiologyFollicleYoung AdultOvarian FollicleTerminology as TopicmedicineHumansOvarian follicleeducationGynecologyeducation.field_of_studySurrogate endpointOvaryObstetrics and GynecologyReproducibility of ResultsAnti-Müllerian hormoneAntral folliclePolycystic ovarymedicine.anatomical_structureReproductive Medicinebiology.proteinFemaleBiomarkersPolycystic Ovary Syndrome
researchProduct

PAN-EX: a pooled analysis of two trials of neoadjuvant chemotherapy followed by chemoradiotherapy in MRI-defined, locally advanced rectal cancer

2016

This analysis confirms that administering neoadjuvant chemotherapy (NACT) before chemoradiotherapy (CRT) could be a potential option for high-risk, locally advanced rectal cancer. In this setting, MRI tumour regression grade is an independent prognostic factor and, when assessed after NACT, may predict the probability and magnitude of incremental benefit from sequential CRT.EXPERT and EXPERT-C were phase II clinical trials of neoadjuvant chemotherapy (NACT) followed by chemoradiotherapy (CRT) in high-risk, locally advanced rectal cancer (LARC). We pooled individual patient data from these trials. The primary objective was overall survival (OS) in the intention-to-treat (ITT) population. Pro…

AdultMale0301 basic medicineOncologymedicine.medical_specialtymedicine.medical_treatmentPopulationPhases of clinical researchKaplan-Meier EstimateDisease-Free Survival03 medical and health sciences0302 clinical medicineInternal medicinemedicineHumansProgression-free survivalStage (cooking)educationNeoadjuvant therapyAgedAged 80 and overeducation.field_of_studyIntention-to-treat analysisRectal Neoplasmsbusiness.industrySurrogate endpointChemoradiotherapyHematologyMiddle AgedMagnetic Resonance ImagingNeoadjuvant TherapyTreatment Outcome030104 developmental biologyOncology030220 oncology & carcinogenesisFemaleNeoplasm Recurrence LocalbusinessChemoradiotherapy
researchProduct

Diagonal ear lobe crease and atherosclerosis : a review of the medical literature and dental implications

2011

In Spain a significant number of individuals die from atherosclerotic disease of the coronary and carotid arteries without having classic risk factors and prodromal symptoms. The diagonal ear lobe crease (DELC) has been characterized in the medical literature as a surrogate marker which can identify high risk patients having occult atherosclerosis. This topic however has not been examined in either the medical or dental literature emanating from Spain. The majority of clinical, angiography and postmortem reports support the premise that DELC is a valuable extravascular physical sign able to distinguish some patients at risk of succumbing to atherosclerosis of the coronary arteries. A minori…

AgingArteriosclerosisGerodontologypanoramic radiographsCoronary Artery DiseaseCardiovascularCoronary artery diseaseCoronary diseasesatherosclerosis diseaseEar Externalmedicine.diagnostic_testStomatognathic DiseasesEar:CIENCIAS MÉDICAS [UNESCO]Heart Diseasemedicine.anatomical_structureOrellaUNESCO::CIENCIAS MÉDICASRadiologyRadiologia dentalcalcified carotid arterymedicine.medical_specialtyPanoramic radiographVital signsArteriosclerosiMalalties coronàriesPanoramicRadiography PanoramicDiagonal ear lobe creasemedicineotorhinolaryngologic diseasesHumansMedical historyEspanyaDental/Oral and Craniofacial DiseaseGeneral DentistryHeart Disease - Coronary Heart DiseaseSurrogate endpointbusiness.industryPreventionReview-ArticleDental radiologyatheromasAtherosclerosismedicine.diseaseOccultExternalRadiographyCoronary arteriesArterioesclerosiOtorhinolaryngologySpainDentistryAngiographySurgerybusiness
researchProduct

Relationship between carotid intima-media thickness and non valvular atrial fibrillation type.

2015

OBJECTIVE: Carotid intima-media thickness (cIMT) is a surrogate marker of subclinical atherosclerosis and it is able to predict both coronary and cerebral vascular events. No data exist on the association between cIMT and non valvular atrial fibrillation (NVAF) type. We conduct this study with the aim to analyze the association between abnormal cIMT and NVAF type. METHODS: A cross-sectional study of the "Atrial fibrillation Registry for Ankle-brachial index Prevalence Assessment-Collaborative Italian Study (ARAPACIS)" has been performed. Among 2027 patients enrolled in the ARAPACIS, 673 patients, who underwent carotid ultrasound examination to assess cIMT, were included in the study. RESULT…

Carotid Artery DiseasesMaleRegistrieSettore MED/09 - Medicina Internagenetic structuresCross-sectional studycarotid intima-media thickness; non valvular atrial fibrillation; ARAPACIScarotid atherosclerosisPredictive Value of TestComorbiditySubclinical atherosclerosiintima-media-thicknessCarotid intima-media thickneRisk FactorsAtrial Fibrillation80 and overPrevalencenonvalvular atrial fibrillation; intima-media-thickness; carotid atherosclerosisRegistriesCarotid intima-media thicknessStrokeAged 80 and overCarotid intima-media thickness; Paroxysmal non valvular atrial fibrillation; Persistent/permanent non valvular atrial fibrillation; Subclinical atherosclerosis; Aged; Aged 80 and over; Ankle Brachial Index; Asymptomatic Diseases; Atrial Fibrillation; Carotid Artery Diseases; Carotid Artery Common; Chi-Square Distribution; Comorbidity; Cross-Sectional Studies; Female; Humans; Italy; Linear Models; Logistic Models; Male; Middle Aged; Predictive Value of Tests; Prevalence; Registries; Risk Factors; Carotid Intima-Media ThicknessMedicine (all)Atrial fibrillationMiddle AgedCommonItalyPredictive value of testsnon valvular atrial fibrillationCardiologycardiovascular systemLinear ModelFemaleCardiology and Cardiovascular MedicineHumanmedicine.medical_specialtyLogistic ModelCarotid Artery CommonPersistent/permanent non valvular atrial fibrillationparoxysmal non valvular atrial fibrillation; persistent/permanent non valvular atrial fibrillation; subclinical atherosclerosis; carotid intima-media thicknessPredictive Value of TestsParoxysmal non valvular atrial fibrillationInternal medicinemedicineHumansAnkle Brachial Indexcardiovascular diseasesSubclinical atherosclerosisCarotid intima-media thickness; Paroxysmal non valvular atrial fibrillation; Persistent/permanent non valvular atrial fibrillation; Subclinical atherosclerosisAgedCross-Sectional StudieAsymptomatic DiseaseCarotid Artery DiseaseChi-Square Distributionbusiness.industrySurrogate endpointRisk Factornonvalvular atrial fibrillationmedicine.diseaseSettore MED/11 - Malattie Dell'Apparato CardiovascolareComorbidityParoxysmal Non Valvular Atrial Fibrillation Persistent/Permanent Non Valvular Atrial Fibrillation Subclinical Atherosclerosis Carotid Intima-Media ThicknessCross-Sectional StudiesLogistic ModelsIntima-media thicknessAsymptomatic DiseasesLinear ModelsARAPACISCarotid ArterybusinessChi-squared distribution
researchProduct